Biological response modifiers in cancer.

摘要: We have seen a surge in the use of immunotherapy for treatment cancer. Biological response modifiers can act passively by enhancing immunologic to tumor cells or actively altering differentiation/growth cells. Active with cytokines such as interferons (IFNs) and interleukins (IL-2) is form nonspecific active immune stimulation. The IL-2 has recently been approved United States Food Drug Administration (FDA) renal cell carcinoma metastatic colorectal Considerable success achieved immunotherapy, especially area passive using monoclonal antibodies--in particular, radiolabeled antibodies. In addition various antibodies that used clinical trials, other strategies antiangiogenic agents matrix metalloprotease inhibitors (MMPIs) also met some success. Recently, FDA bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, melanoma. This review sheds light on angiogenesis increasing thalidomide cancer, upcoming potential cancer vaccines designed activate cell-mediated responses against antigens.